医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PURE Bioscience Receives Order for Shipment of PURE® Hard Surface Disinfectant to Asia

2020年03月16日 PM10:04
このエントリーをはてなブックマークに追加


 

RANCHO CUCAMONGA, Calif.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced it received a purchase order to ship EPA-registered PURE® Hard Surface disinfectant to Harmony Bioscience, a distributor in Asia with various locations. Harmony Bioscience holds Asian import and sales permits for PURE Hard Surface disinfectant. PURE Chairman and CEO Tom Y. Lee is an affiliate of Harmony Bioscience.

The order is for RTU (ready-to-use) and is expected to ship by sea in early April to Harmony International Holdings Co., Ltd. (Hong Kong). From there, PURE Hard Surface disinfectant will then be redistributed to Taiwan Harmony Eco-Science Col, Ltd. and Guangzhou Harmony Eco-Science Co., Ltd. (China). The product will then be resold for institutional, janitorial, consumer, hospital and school use. A smaller initial shipment was sent by air last week to Hong Kong.

Lee said, “We are pleased that the years of work to prepare us to expand our domestic sales of our powerful and non-toxic antimicrobial solution into the Asian market are beginning to pay off. We are hopeful that this is the first of what could become future, recurring orders.

“PURE Hard Surface disinfectant – which has kill times as fast as 30 seconds and is also registered for use on food contact surfaces – is being used in the U.S. by food transport companies, restaurants, produce processors and more than 100 processors/manufactures as a proven and effective disinfection solution,” Lee concluded.

Since 2011, the U.S. EPA has registered PURE Hard Surface disinfectant to be effective on a wide range of pathogens, including:

  • Human Coronavirus, Influenza, Listeria, Norovirus, Salmonella and E. coli, and in a wide variety of environments, including:
  • Medical, food processing, food service, public transportation, home/children/pets, janitorial & institutional (schools, office buildings, prisons, government installations, etc.) and other areas.

Superior Efficacy: Eco-Friendly Sanitization Solution on Hard, Non-Porous, Environmental and Food Contact Surfaces

  • Fast and effective – quickly kills germs, including Human Coronavirus, Influenza, Listeria, Norovirus, Salmonella, E. coli and other pathogens – with kill times as fast as 30 seconds
  • Eliminates both enveloped and non-enveloped viruses
  • No rinse required – including food contact surfaces
  • EPA-registered hospital disinfectant
  • Odorless and non-irritating with no hazard warnings on label
  • Ready-to-use; offers 24-hour residual protection, contains no bleach, ammonia, phosphates, phenols or VOCs (volatile organic compounds)
  • Lowest EPA toxicity rating – Category IV

Mode of Action – How It Works

SDC’s rapid and broad-spectrum efficacy is largely attributed to its dual mechanisms of action and unique characteristics. PURE’s ‘Trojan Horse’ mode of action video is available at https://www.purebio.com/technology/silver-dihydrogen-citrate-sdc.htm.

PURE Hard Surface Disinfectant U.S. Customers

  • Truck sanitization solution for food safety transportation use by some of the largest foodservice distribution companies
  • Produce processing plants and equipment
  • Blue chip and other national casual dining restaurants and QSR (quick service restaurant) chains
  • Environmental and surface disinfection solution for processing and manufacturing plants (including for baked goods, ready-to-eat foods, pet foods, tortillas, dairy products, meats, poultry and produce)

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena — providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE is headquartered in Rancho Cucamonga, California (San Bernardino metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2019 and Form 10-Q for the second fiscal quarter ended January 31, 2020. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005166/en/

CONTACT

Mark Elliott, VP Finance

PURE Bioscience, Inc.

melliott@purebio.com

Ph: 619-596-8600 Ext: 116

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Intralink-Spine, Inc. Adds Clinical Sites in Australia
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market
  • ISTH 2020虚拟大会将呈报的新数据展示Octapharma对出血性疾病患者的承诺
  • MetLife’s 360Health Wins Gold Stevie®
  • PHC株式会社:配薬支援および決済サービスを実現した「ヘルスケア手帳」サービスを導入-患者さんへの医療サービス向上を目指したクラウドサービス連携ソリューション「Medicom Cloudコネクト」第一弾